Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase 2 in epithelial ovarian cancer.
OBJECTIVE
We investigated the prognostic significance of extracellular matrix metalloproteinase inducer (EMMPRIN) and matrix metalloproteinase 2 (MMP-2) in epithelial ovarian cancer as well as their relation to hyaluronan (HA) expression.


METHODS
The expression of EMMPRIN and MMP-2 was analyzed immunohistochemically in 295 primary epithelial ovarian cancer patients and 67 metastases.


RESULTS
A low membranous EMMPRIN expression was detected more often in serous tumors than in other types (p < 0.0005) and it was associated with tumors of advanced stage (p = 0.012) or with a large primary residual (p = 0.011). A low expression of MMP-2 in cancer cells was associated with a high histologic grade (grade 3) of the tumor (p = 0.005) and endometrioid type of tumors (p < 0.0005). Stromal MMP-2 expression was significantly associated with strong stromal HA expression (p = 0.002, r = 0.187). In univariate analysis, 10-year disease-related (DRS) and recurrence-free survivals were significantly better when MMP-2 expression in cancer cells was high (p = 0.0057 and p = 0.0467, respectively). DRS was also better when membranous EMMPRIN expression was high (p = 0.013). In multivariate analysis, strong MMP-2 in cancer cells (RR = 1.48, CI = 1.07-2.04, p = 0.017) indicated favorable DRS.


CONCLUSIONS
Our results show that EMMPRIN and MMP-2 in cancer cells are significant indicators of a favorable prognosis of epithelial ovarian cancer.
Sillanpää
S
S
Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Kuopio, Kuopio, Finland.
Anttila
M
M
Suhonen
K
K
Hämäläinen
K
K
Turpeenniemi-Hujanen
T
T
Puistola
U
U
Tammi
M
M
Sironen
R
R
Saarikoski
S
S
Kosma
V-M
VM
D018262:Adenocarcinoma, Clear Cell / Q000737:chemistry / Q000401:mortality; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D051926:Basigin / Q000032:analysis*; D002277:Carcinoma / Q000737:chemistry* / Q000401:mortality; D018269:Carcinoma, Endometrioid / Q000737:chemistry / Q000401:mortality; D002462:Cell Membrane / Q000737:chemistry; D018282:Cystadenocarcinoma, Mucinous / Q000737:chemistry / Q000401:mortality; D018284:Cystadenocarcinoma, Serous / Q000737:chemistry / Q000401:mortality; D018291:Cystadenoma, Mucinous / Q000737:chemistry / Q000401:mortality; D018293:Cystadenoma, Serous / Q000737:chemistry / Q000401:mortality; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006820:Hyaluronic Acid / Q000032:analysis; D020778:Matrix Metalloproteinase 2 / Q000032:analysis*; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis*; D010051:Ovarian Neoplasms / Q000737:chemistry* / Q000401:mortality; D011379:Prognosis; D016037:Single-Blind Method; D017154:Stromal Cells / Q000737:chemistry
C497886:BSG protein, human; D009363:Neoplasm Proteins; D051926:Basigin; D006820:Hyaluronic Acid; D020778:Matrix Metalloproteinase 2